Jan
17

Congratulations, Pat – and you too, PMSI

I’ve been remiss in not congratulating Pat Sullivan on his new position as head of PMSI’s Ancillary Services Division. [opens pdf] Pat’s a long time friend and colleague, and is one of those people universally respected for his business acumen, breadth of experience, and depth of character.
PMSI had been looking for a leader for Ancillary Services for several months (if not more), had carefully considered several candidates and took pains to ensure they picked the right person to lead a business that has been described by sources as critical to the future of the organization.
Over the near term, I’d expect an important part of Pat’s new role will be to solidify PMSI’s position as the third largest provider of MSA services. With the announcement in December of the sale [opens pdf] of industry leader Crowe Paradis (for $90 million to Verisk), the MSA vendor business is once again in the spotlight. I’d expect the top companies in the space, (Crowe, PMSI, and perhaps a couple boutique firms) will push ahead of their smaller/less agile/less technically adept competitors. The business is becoming increasingly capital-demanding and reliant on strong IT, and the downside of not ‘getting it right’ is getting more painful every month.
I didn’t include Gould & Lamb in that list, as I’ve heard several times they’ve had challenges on the technical side that may have contributed to the management shakeup last fall. We’ll have to wait and see if the issues are resolved.
These are indeed interesting times in the MSA business; CMS appears to be getting the message about reporting and AWP and other lines (liability et al) are starting to think about their exposure. The insular nature of the business and many of the companies in it has led to far too much internal focus and nowhere near enough consideration of how – and where – MSAs can best ‘fit’ into the vendor/supplier.
I’m expecting that will change.
What does this mean for you?
Nice to know good guys succeed.

Disclosure – PMSI is NOT a consulting client. They – and seven other PBMs – are members of CompPharma LLC.


Jan
14

Guidelines – beyond the soundbite and marketing hype

Is medicine science, art, some combination of the two, or something else?
That’s not an idle question.
If you’re trying to get more scientific about how you practice medicine or what services/procedures/drugs/treatments you pay for, you are likely relying on clinical guidelines to help provide a little more perspective, hopefully one based on something other than best guess or generally accepted knowledge or tribal wisdom.
A recent study may well give you pause – the key finding is rather alarming – many guidelines are NOT based on solid research, but on work that is kindly described as rather more superficial.
Published in the Archives of Internal Medicine, the research found “More than half of the current recommendations of the IDSA (Infectious Diseases Society of America) are based on level III evidence [expert opinion] only.” [emphasis added] Note that the research focused solely on IDSA guidelines, which cover a relatively small fraction of all the guidelines in use today. Largely as a result of that conclusion, the researchers concluded “Until more data from well-designed controlled clinical trials become available, physicians should remain cautious when using current guidelines as the sole source guiding patient care decisions.”
This isn’t exactly new news. This from research on guidelines published in The Journal of the American Medical Association over a decade ago “Less than 10% of the guidelines used and described formal methods of combining scientific evidence or expert opinion. Many used informal techniques such as narrative summaries prepared by clinical experts, a type of review shown to be of low mean scientific quality and reproducibility.18​ Indeed, it was difficult to determine if some of the guidelines made any attempt to review evidence, as less than 20% specified how evidence was identified, and more than 25% did not even cite any references.”
The risk here is our sound bite-long attention span will lead some to use these studies to discount guidelines in their entirety, ignoring entirely the “Until more data from well-designed controlled clinical trials become available” recommendation.
Truth is there are lots of guidelines based on standards of evidence significantly higher than ‘expert opinion’. The pre-eminent organization in this area, and the one with the most rigorous standards, is the Cochrane Collaboration. And while not all will meet the randomized double-blind control methodology that most believe is the gold standard, many will indeed provide an ample and durable foundation on which to base medical decisions, treatment recommendations, and reimbursement.
With that said, there are organizations that trumpet their ‘guidelines’ as providing the basis for coverage and payment decisions, when a more-than-superficial examination indicates the ‘guidelines’ are built on mighty shaky ground.
The Agency for Healthcare Research and Quality maintains a database of evidence-based clinical guidelines; the listing is not comprehensive as many organizations choose to not submit their guidelines for business reasons. However, while not meeting the ‘gold’ standard described above, the standard employed by AHRQ is far superior to that of “expert opinion only”; AHRQ requirements include “Corroborating documentation can be produced and verified that a systematic literature search and review of existing scientific evidence published in peer reviewed journals was performed during the guideline development.” (while their science is solid, they really need to get some English majors involved in the whole writing thing…)
What does this mean for you?
If an organization or vendor is touting their medical criteria or guidelines, prepare – and ask – pointed questions about the methodology, development process, quality of the evidence, and staffing of the effort. The good ones will be only too happy to share their work, and the others will either not know why you aren’t impressed and/or be exposed.

A thoughtful piece on ranking the evidence used in medical guideline development can be found here. [opens pdf]
Lots more info on guidelines is available here.


Jan
12

Physician dispensing in comp – the right way

A commenter (thanks Greg) on my post yesterday re NCCI’s research on physician dispensing noted “Going after the physicians, who are making efforts to recoup their steadily declining reimbursements, does not seem like the best strategy.”
Greg’s got a good point. There are many docs and occ med clinics that are dispensing medications for the right reasons, and not looking to make exorbitant profits. While their intentions are honorable, there are a couple concerns that bear mentioning.
First, as noted yesterday (and other times here on MCM) the proponents of physician dispensing often cite increased patient compliance, reduced hassle for the patient, and increased generic dispensing as justification/rationale for dispensing meds to the patient from the doctor’s office. I’ve not seen any studies that support the claim of increased compliance (I’ve seen claims that refer to studies but not the studies themselves. That said,I’ll stipulate that compliance is likely better when docs dispense drugs.
But, in addition to the higher costs perpetuated by repackagers and physician dispensing technology/services companies, there’s another potential concern with physician dispensing. Work comp claimants are usually treated by docs that haven’t seen the claimant before the occupational injury. While the WC doc certainly asks about prior medical history, current medications and the like, it is not uncommon for patients to forget which meds they take or be unable to accurately identify their drugs.
Not so big an issue if the claimant goes to their usual pharmacy, where the system will identify any potential conflicts and notify the dispensing pharmacist (assuming the claimant doesn’t go to a new pharmacy).
Potentially a bigger issue arises if the treating doc doesn’t get the full story, prescribes and dispenses meds that conflict with the claimants’ other meds. While there are some databases and sources of prescription data that docs may be able to tap into (or so I’m told), I don’t know if many of the physicians dispensing meds are doing so today – or, for that matter, even know of these resources.
That’s not to say the pharmacist’s database is foolproof – it most certainly isn’t. However, it’s a lot better than no database – or not accessing a database – at all.
In my view, physician dispensing can be appropriate if:
a) the price is pegged to the original manufacturer’s AWP, not some fabricated price from a repackager or dispensing services company;
b) the medications are appropriate and consistent with generally approved standards of care; and
c) the physician accesses the appropriate databases to verify the medication prescribed is safe for that particular patient.


Jan
11

Physician dispensing in work comp – worse than you think

The good folks at NCCI just released research which focuses attention on what looks to be the fastest growing part of the work comp medical dollar – drugs dispensed by physicians.
The lead sentence in their annual update[opens pdf] on prescription drug costs puts it bluntly: “The volume of prescription drugs dispensed by physicians to workers compensation (WC) claimants has risen sharply in recent years–putting upward pressure on WC costs.” [emphasis added]
While that’s bad enough, the current situation is likely worse. Why? NCCI based their report on 2008 data. If the 2007 – 2008 trend (excluding California) continued for 2009/10, physician dispensed drugs accounted for 64% of total spend last year.
Between 07 and 08, physician dispensed drugs went from about 8% of drug spend to about 16%. Now, I don’t believe the trend continued for two more years; I also don’t believe it went down. Therefore, I’m betting physician dispensed drugs accounted for somewhere between a fifth and a quarter of drug spend in 2010.
While you’re digesting that, here are a few more factoids to ruin your lunch.
The study, authored by Barry Lipton, Chris Laws, and Linda Li and based on 2008 data, goes on to report:
physician dispensing has increased in most states, with particularly large increases seen in southeastern and central midwestern states
Georgia saw physician dispensed drugs hit about 30% of all drug costs, Florida hit about 45%, with Hawaii, Michigan, and Maryland all in the mid-to-upper twenties
– dispensing is increasing for new and old claims; my bet is the growth in dispensing the initial script means there will be a downstream growth in dispensed drugs.
I don’t believe all docs are just dispensing drugs to make more money. I do know the profits for docs and the dispensing companies can be enormous.
More on when, where, why, and how physician dispensing may be appropriate later this week.


Jan
10

Aetna work comp talent

My post earlier today re the changes at Aetna Workers’ Comp Access inspired several calls and emails from employers seeking information on the folks who were laid off, as they may have skills, experience, and expertise needed by work comp network and managed care firms.
I’m not – nor do I ever want to be – an employment counselor, but if anyone from AWCA wants to shoot me their resume I’ll pass it on to the interested parties.
Confidentiality assured – promise. I’ll vet the potential hirers and will pass on resumes only to those who appear ‘real’.
email me at infoAThealthstrategyassocDOTcom.


Jan
10

What’s up with Aetna’s work comp unit?

Last week several of the folks responsible for managing new business and existing clients for Aetna’s Work Comp unit were laid off. Not exactly a great way to start 2011.
This came after a year plus in which AWCA’s network customers were increasingly plagued by problems associated with poor provider data quality and provider relations issues, complicated by a lack of responsiveness from Aetna.
With that background, it’s not exactly surprising that AWCA cut its work force; without much to say to clients it didn’t make much sense to have a staff that was supposed to be doing the talking. I would note that the customer-facing staff were in the rather uncomfortable rock-and-a-hard-place position, stuck between Aetna’s networks ops staff and policies, and their work comp payer customers who weren’t getting the answers they wanted – or, quite frankly, deserved.
Originally, AWCA was set up as an individual business unit led by Pat Scullion. AWCA’s individual functions were separated out several years ago, and now reside in different operating units within mother Aetna. Furthermore, there is no one leader or advocate for the entire AWCA ‘program’ – provider relations, compliance, customer service, account management, IT – so the folks doing the work have other things to do, other things that may, or may not, be higher on the priority list.
Aetna’s work comp ‘network’ has been plagued with lousy provider data quality in several states for as long as I can recall; Pennsylvania among the most problematic. The problem manifests itself when employers post panels, or lists, of providers accepting workers comp, only to find some/many of the docs don’t take comp patients, aren’t at that address, don’t answer that phone number, and/or claim they aren’t in the AWCA network. The employer then complains to the insurer, who then calls the network – and in the case of AWCA, often to no avail.
What makes this interesting are the downstream implications for payers, other network vendors, and providers. Aetna is the defacto network – or a major part of the network – for Coventry in a couple dozen states. Many large payers – Liberty, AIG, Travelers, Sedgwick, Hartford – work with Aetna directly or through Coventry. It remains to be seen if the layoff is limited to customer-facing staff or there will be further changes at ‘AWCA’.
UPDATE – two sources called to let me know that AWCA has told some of their direct clients that they will no longer service them directly, as they are not large enough to merit a direct relationship with AWCA. Instead, these clients will have to access AWCA through another entity – usually Coventry.
That said, the termination of these professionals hasn’t been good news for AWCA’s clients. Some see this as the latest in the de-evolution of what had been a promising network alternative.
On a personal note, there’s some talent now on the street; companies looking for network ops and sales personnel may want to reach out to the (now former) AWCA people.


Jan
6

Why all the deals in the work comp space?

The investment community’s fascination with the work comp services space resulted in a half-dozen deals over the last couple of months, on top of several more earlier in 2010.
Which has led some to ask? Why this industry and why now?
The ‘macro’ answer to the ‘why now’ question has to do with the tax treatment of investments, the expiration of the Bush tax cuts, and a desire on the part of many owners to cash out before those cuts expired. While they didn’t, the work was still well under way by the time the final deal was cut so things just kept moving.
There’s also a LOT of money sloshing around in investors’ bank accounts waiting to be used, and lots of pressure on private equity firms to put that money to use.
The ‘micro’, or industry-specific answer is a little more complex.
First, private equity loves immature, technology-starved, process-heavy, decentralized businesses. By rolling up similar companies, investing in technology, standardizing processes and hiring strong leaders, owners can reap outsize rewards through increased efficiency, the removal of competitors, and lower cost structures.
Second, the comp industry has been moribund of late, stuck in the mud due to declining frequency, low claims volume, excess capacity (in insurance, claims administration, and related services) and a horrendous employment picture. But that’s about to turn. According to an analysis by JMP Securities, “For the 2010/2011 filing season, 13 states increased rates compared to 8 in the prior period. Importantly, rates are rising in some of the largest states including CA, FL, and IL (collectively 27% of nationwide workers’ comp premiums).”
Now that hiring is improving and injuries are trending up, investors expect to see significant organic growth. This growth may be somewhat artificial as it’s coming after several awful years, and will in all likelihood taper off a couple years out, but it’s growth nonetheless.
Third, many of the companies that populate the comp trade show floors were founded a couple decades ago by entrepreneurs, some of whom are now looking to take a few chips off the table. For those that have worked smart and hard, those chips have lots of zeros attached.
Fourth, over the last decade, TPAs (well, many TPAs) have changed their business model from making money from claims handling fees to making more money from managed care and claim service fees. This pumps up the top line and profits. The more aggressive TPAs have pushed beyond collecting fees and commissions from vendors to acquiring them outright, further enhancing their financials. This isn’t necessarily a bad thing, as long as their customers know where their dollars are going.
What does this mean for you?
Make sure your contracts have a survivability or change in control clause.


Jan
5

Well, that didn’t take long – the GOP ‘rethinks’ its commitment

UPDATE – yesterday I reported on GOP House members’ commitment to cut a hundred billion from the discretionary spending this fiscal year (which, by the way, started October 1, 2010). After I posted this piece, the GOP reneged on the commitment, with aides to Speaker Boehner saying the $100 billion figure was ‘hypothetical’.
No, it wasn’t.
In the ‘Pledge to America’ the signatories said “We will roll back government spending to pre-stimulus, pre-bailout levels, saving us at least $100 billion in the first year alone.”
In a speech at the time of the midterm elections, Boehner himself committed to that number, saying “We’re ready to cut spending to pre-stimulus, pre-bailout levels, saving roughly $100 billion almost immediately.” (note Boehner’s website had the link up yesterday, it doesn’t work today.)
So why is this in a blog focused on health care?
Simple. The GOP has committed to overturning, or at the least de-funding, health reform. Not some of the Accountable Care Act – all of it.
That includes:
– the prohibition against medical underwriting that effectively prevents those of us with pre-existing conditions from obtaining individual coverage in most states.
the closing of the doughnut hole in Part D that will save seniors thousands on their drug bills
– the requirement (already in place) that insurers cover kids till age 26

– the requirement (already in place) that prohibits medical underwriting or pre-ex exclusion for kids
vouchers for less-well off folks to use to help cover the cost of insurance
– prohibition on lifetime maximum coverage limits
I find it…interesting that many of the same folks who passed Part D and its $16 trillion addition to the deficit in an attempt – successful at that – to woo seniors, would now want to upset seniors, and moms, and families by killing provisions that most voters like.
We’ll see.


Jan
4

Deals aplenty in work comp, and now news of one more…

The investment community finished 2010 in a frenzy of deal making – Odyssey sold York Claims to ABRY, Progressive Medical was bought by Stone Point, Genex bought Intracorp from CIGNA for stock, Sedgwick is buying SRS, Humana bought Concentra – and I’m sure there are others I’m forgetting. Now, just when you thought it was time to take a breath, along comes info that another deal is done.
Word[opens pdf] is that Genex has bought PT manager Network Synergy Group.
[note release came out after initial publication of this post]
NSG will operate as a separate organization under Genex with current leader John Hanselman staying on as NSG head.
How this will work at Genex is TBD; their current PT network provider is Universal SmartComp, whose President, Chris Feeney, has strong ties to Genex’ founders. I find it hard to believe Genex will switch their business from USC to NSG, but Genex wouldn’t have bought NSG unless there was some significant financial – or strategic – benefit.
This will be interesting to watch.
This is the latest in a series of ‘recent work comp space’ deals that involve Stone Point – who owns Genex, third party biller Stone River (and soon Progressive Medical), and a chunk of Sedgwick. Less recently, Stone Point acquired TPA Cunningham Lindsey and did a joint venture with broker Lockton to purchase Alexander Forbes International Risk Services (AFIRS), an international insurance broker. Stone Point, like ABRY Partners, is staking out a major position in the work comp services business, consolidating their holdings, adding service providers and rolling up TPA business while taking out competitors.
While the Genex-NSG deal is almost certainly one of the smallest in terms of valuation, it is yet another indication of the drive to increase top line revenues that appears to be a major driver of private equity’s work comp strategy.